Applied Genetic Technologies Corporation Deferred Revenue 2011-2026 | AGTC

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Applied Genetic Technologies Corporation

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	6.3 M	21 M	46.9 M	-	-	212 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
46.9 M	212 K	18.6 M

Quarterly Deferred Revenue Applied Genetic Technologies Corporation

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.7 M	16.3 M	6.3 M	8.19 M	11.9 M	14.7 M	21 M	21 M	-	-	46.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
46.9 M	6.3 M	17.7 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	6.68 M	$ 2.08	-14.4 %	$ 214 M	USA
Acer Therapeutics ACER	2.91 M	-	2.71 %	$ 14 M	USA
Altimmune ALT	19.8 K	$ 4.2	-2.67 %	$ 298 M	USA
Aprea Therapeutics APRE	529 K	$ 0.88	-3.72 %	$ 3.18 M	USA
Aptevo Therapeutics APVO	811 K	$ 7.2	-1.64 %	$ 1.99 M	USA
I-Mab IMAB	563 K	-	-	$ 866 M	China
Aquestive Therapeutics AQST	1.05 M	$ 4.1	2.37 %	$ 356 M	USA
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Arcturus Therapeutics Holdings ARCT	19.5 M	$ 8.35	1.46 %	$ 225 M	Israel
Ardelyx ARDX	1.21 M	$ 6.37	-2.75 %	$ 1.54 B	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
argenx SE ARGX	37.8 M	$ 756.71	-1.33 %	$ 25 B	Niderland
Armata Pharmaceuticals ARMP	245 K	$ 10.91	1.58 %	$ 394 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
Arvinas ARVN	71.3 M	$ 12.97	-2.3 %	$ 920 M	USA
Arrowhead Pharmaceuticals ARWR	2.4 M	$ 61.74	-2.42 %	$ 8.26 B	USA
Ascendis Pharma A/S ASND	363 K	$ 231.56	-0.83 %	$ 5 B	Danmark
Alterity Therapeutics Limited ATHE	33.3 K	$ 3.39	-1.63 %	$ 8.16 B	Australia
Actinium Pharmaceuticals ATNM	1 M	$ 1.17	-0.85 %	$ 35.2 M	USA
Atossa Therapeutics ATOS	48.2 K	$ 4.39	-0.9 %	$ 553 M	USA
Aurinia Pharmaceuticals AUPH	3.72 M	$ 14.14	-0.21 %	$ 1.9 B	Canada
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	1.85 M	-	-	$ 86.2 M	USA
AIkido Pharma AIKI	240 K	-	1.93 %	$ 17.4 M	USA
Anavex Life Sciences Corp. AVXL	70.5 K	$ 4.54	2.44 %	$ 387 M	USA
Axon Enterprise AXON	613 M	$ 570.5	5.18 %	$ 43.2 B	USA
Aytu BioScience AYTU	339 K	$ 2.56	-0.58 %	$ 16.1 M	USA
AlloVir ALVR	2.66 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	35.6 M	-	-	$ 2.17 B	USA